SCWorx Corp. filings document the regulatory record for a healthcare SaaS data management company and its common stock. The company’s 8-K reports cover Nasdaq minimum-bid-price notices, reverse stock split actions, warrant inducement agreements, and other material events tied to capital structure and listing compliance.
Its registration and proxy filings describe securities offerings, common stock and warrant issuance, shareholder voting matters, director elections, executive compensation advisory votes, auditor ratification, and Nasdaq Rule 5635(d) share-issuance approvals. These disclosures also frame governance, capital authorization, and financing terms for the business.
SCWorx Corp. (WORX) registered up to 8,253,352 common shares for resale by selling stockholders: 399,860 shares already issued and up to 7,853,492 shares issuable upon exercise of warrants. After effectiveness, selling stockholders may sell at prevailing market prices, prices related to prevailing prices, or privately negotiated prices. SCWorx will receive no proceeds from those resales.
SCWorx may receive up to approximately $20.1 million in aggregate gross proceeds if all warrants are exercised for cash; cashless exercises produce no cash for the company. Any such proceeds are intended for working capital and general corporate purposes. Common shares outstanding were 1,387,099 as of October 21, 2026. SCWorx states warrant exercises would dilute existing stockholders and that all warrants other than the September Warrants may have exercise-price reductions that increase the shares issuable.
SCWorx Corp. is registering up to 8,253,352 common shares for resale by selling stockholders: 399,860 already-issued shares and up to 7,853,492 shares issuable upon warrant exercise. Resales may occur from time to time after the registration statement becomes effective; SCWorx will receive no proceeds from those sales.
SCWorx may receive up to approximately $20.1 million in aggregate gross proceeds if all warrants are exercised for cash, for working capital and general corporate purposes; certain warrants permit cashless exercise, in which case SCWorx would receive no cash. Common shares outstanding were 1,387,099 as of October 21, 2026. The prospectus says substantial sales could depress the share price and warrant exercises will dilute existing stockholders; warrants other than the September Warrants may have adjustments that reduce exercise prices and increase shares issuable. Nasdaq's Hearings Panel granted reconsideration of its delisting decision on October 2, 2026, and trading resumed October 7 subject to conditions. SCWorx says it cannot assure compliance with Nasdaq's continued listing requirements during the Panel Monitor period or thereafter.
SCWorx Corp. is registering for resale by selling stockholders up to 13,099,253 shares of common stock. The shares include previously issued common stock and shares issuable upon warrant exercise. After the registration statement becomes effective, selling stockholders may offer shares in public or private transactions at prevailing, related, or privately negotiated prices.
SCWorx will receive no proceeds from selling-stockholder resales. It may receive up to approximately $32.5 million in aggregate gross proceeds if all warrants are exercised for cash; certain warrants may be exercised on a cashless basis, in which case the company would receive no cash. SCWorx intends to use any cash proceeds for working capital and general corporate purposes. Warrants other than the September Warrants may have exercise-price adjustments that reduce the exercise price and increase the shares issuable.
Common shares outstanding were 742,099 as of October 9, 2026. SCWorx says substantial sales could depress its share price and warrant exercises would dilute existing stockholders. Nasdaq trading resumed October 7, 2026, after the Hearings Panel granted reconsideration of a delisting decision, subject to panel conditions; SCWorx says it cannot assure continued compliance with Nasdaq’s continued listing requirements during the Panel Monitor period or thereafter.
SCWorx Corp. (WORX) said Nasdaq’s Hearings Panel granted reconsideration on October 2, 2026, and approved continued listing on The Nasdaq Capital Market after finding compliance with the minimum bid-price and publicly held-share rules. Publicly held shares were 549,092 as of September 17, above the 500,000 minimum; the closing bid was at least $1.00 on every trading day since August 4. Nasdaq trading, suspended since April 14, is to resume on a date Nasdaq schedules after the company files this report and submits Nasdaq’s reinstatement form on October 5, 2026; until then, the stock remains quoted on OTCQB.
Approval includes a one-year Panel Monitor ending October 2, 2027, and monthly reports on shares outstanding, insider holdings and public float through October 5, 2027. A continued-listing failure during monitoring would mean no compliance plan or cure period and prompt a Staff Delisting Determination, which SCWorx may appeal.
Private-placement purchasers waived termination rights based on the September 17 decision, but retain rights if Nasdaq trading does not resume by October 31, 2026, or if the stock is delisted because of that decision and a Form 25 is filed. If all purchasers terminate under those rights, SCWorx would return $938,000; 350,000 shares and warrants to purchase 350,000 shares would be canceled.
SCWorx Corp. (WORX) ownership disclosure states that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC may each be deemed to beneficially own the same 50,000 shares held by Intracoastal. As of September 23, 2026, each had shared voting and dispositive power over those shares, representing approximately 9.1% of common stock based on 550,000 shares outstanding following September 16, 2026, as reported to them by SCWorx.
Another 50,000 shares issuable under Intracoastal’s warrant are excluded because the warrant limits exercise when it would cause beneficial ownership, together with affiliates and any group members, to exceed 4.99%. Without that blocker, each reporting person may have been deemed to beneficially own 100,000 shares.
SCWorx Corp. requested reconsideration of Nasdaq’s decision to delist its common stock after a September 16, 2026 private placement of 350,000 shares and warrants to purchase 350,000 shares closed. Including exercises of existing warrants and shares issued to the placement agent, the transactions resulted in 449,860 shares issued. The company believes it now has more than 500,000 publicly held shares and has cured that deficiency; its request remains pending. WORX continues to be quoted on the OTCQB Venture Market.
To regain compliance with Nasdaq’s Bid Price Rule, SCWorx must evidence a closing bid of at least $1.00 per share for 10 consecutive trading days by October 5, 2026. The company will treat purchaser termination notices delivered by October 15, 2026 as timely. If all purchasers exercise their rights, SCWorx would return $938,000 and cancel the placement’s 350,000 shares and warrants to purchase 350,000 shares, reducing its publicly held shares.
SCWorx Corp. (WORX) entered into a Securities Purchase Agreement with ten accredited investors for a private placement of 350,000 shares of common stock and warrants for 350,000 shares, at a combined purchase price of $2.68 per share and warrant, generating $938,000 in gross proceeds on September 16, 2026.
Each warrant is immediately exercisable at $2.56 per share and has a five-year term, with a 4.99% (or 9.99%) Beneficial Ownership Limitation and cashless exercise if resale registration is unavailable. SCWorx agreed to file a Form S-3 to register the resale of the warrant shares and to keep the private placement proceeds in a segregated deposit account for 90 days.
The company engaged Dawson James Securities as exclusive placement agent for 12 months and agreed to issue 49,860 “Fee Shares” (9.99% of post-closing shares) plus cash fees of 5.0% of private placement and warrant-exercise proceeds and 6.0% of subsequent offerings, and accepted a 90-day restriction on new issuances and a one-year prohibition on “variable rate transactions.” Purchasers can rescind their investment and receive cash repayment if Nasdaq trading does not resume by October 31, 2026 or if a delisting determination is received before then.
SCWorx Corp. (WORX) reports that Nasdaq has notified the company it no longer meets Nasdaq Listing Rule 5550(a)(4), which requires at least 500,000 publicly held shares for continued listing on The Nasdaq Capital Market. As of the company’s September 1, 2026 confirmation to Nasdaq, it had 89,782 publicly held shares, creating an additional basis for delisting.
The notice follows a previously completed 1‑for‑12 reverse stock split, effective August 3, 2026, which helped the stock close at or above $1.00 for twenty consecutive trading days but reduced the number of publicly held shares. Because the reverse split caused non‑compliance with the publicly held share standard, Nasdaq rules treat SCWorx as still non‑compliant with the minimum bid price requirement until it first regains compliance with the publicly held share and market value of publicly held shares tests and then maintains a closing bid price of at least $1.00 for the required period.
The company also remains below the $1,000,000 market value of publicly held shares requirement, for which Nasdaq has provided a compliance period expiring January 20, 2027. SCWorx is evaluating alternatives, including issuing additional common shares, which it states would be dilutive and could pressure the share price, and it plans to submit written views to the Nasdaq Hearings Panel by September 9, 2026. The company cautions there is no assurance it will regain compliance or avoid delisting.
SCWorx Corp. reported modest revenue growth and sharply improved profitability for the quarter and six months ended June 30, 2026. Quarterly revenue was $706,049, up slightly from $682,632, while gross profit rose to $330,423 from $180,417, an increase of approximately 83%, driven mainly by lower cloud hosting and contractor costs.
For the six-month period, revenue was $1,450,948 versus $1,402,931, and gross profit more than doubled to $704,532. Operating expenses were relatively stable at $961,300, but non-cash interest and settlement charges declined sharply, reducing net loss to $294,721 from $2,382,388. Cash decreased to $1,263,478 as the company used $258,442 in operating cash flow and invested $138,021 in capitalized software development, partially offset by warrant exercise proceeds.
Total assets were $7.7 million, including $5.84 million of goodwill and $158,040 of capitalized intangibles. Deferred revenue increased to $198,125, reflecting remaining SaaS performance obligations. SCWorx effected a 1‑for‑12 reverse stock split in August 2026 to support Nasdaq bid-price compliance and is in a 20‑day monitoring period. Management disclosed that disclosure controls and procedures were not effective due to internal control design deficiencies and limited segregation of duties.